A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Article in Annals of Hematology (August 2024)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Article in Annals of Hematology (August 2024)
Article in Leukemia & Lymphoma (June 2024)
Article in Infectious Diseases and Therapy (May 2024)